2,127 results match your criteria Primary CNS Lymphoma


Promising effect of PDL1 inhibitors in the front-line management of primary aggressive central nervous system lymphoma: A case report.

Hematol Oncol Stem Cell Ther 2020 Jun 30. Epub 2020 Jun 30.

Department of Hematology, Kuwait Cancer Control Center, Kuwait. Electronic address:

Primary central nervous system lymphoma (PCNSL) is a rare lymphoma that involves the central nervous system. The standard treatment involves chemotherapy with high-dose methotrexate. To the best of our knowledge, this is the first reported case of employing checkpoint inhibitor, nivolumab, alone to treat a patient with PCNSL who could not tolerate the induction therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hemonc.2020.06.003DOI Listing

Nivolumab for Treatment of Progressive Multifocal Leukoencephalopathy in Sézary Syndrome.

Eur J Neurol 2020 Jul 9. Epub 2020 Jul 9.

Department of Neurology, Ruprecht-Karls-Universität Heidelberg Medizinische Fakultät Mannheim, Mannheim, Germany.

Progressive multifocal leukoencephalopathy (PML) is a rare but severe opportunistic CNS infection caused by JC polyomavirus in immunosuppressed patients. Immune checkpoint blockade stimulates immune function and has been suggested to reinvigorate viral clearance in PML patients by expanding JCV-specific T cells . Among the first 13 published PML patients treated with programmed cell death 1 inhibitors (PD1I) 8 showed a mild to marked treatment response . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ene.14433DOI Listing

Distinct topographic-anatomical patterns in primary and secondary brain tumors and their therapeutic potential.

J Neurooncol 2020 Jul 8. Epub 2020 Jul 8.

Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Purpose: Understanding the topographic-anatomical patterns of brain tumors has the potential to improve our pathophysiological understanding and may allow for anatomical tailoring of surgery and radiotherapy. This study analyzed topographic-anatomical patterns underlying neuroepithelial tumors, primary CNS lymphoma and metastases.

Methods: Any histologically confirmed supra- or infratentorial parenchymal neoplasia of one institution over a 4-year period was included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-020-03574-wDOI Listing

Primary Large B-cell Lymphoma of the Central Nervous System with Cyclin D1 Expression and t(11;14) (CCND1-IGH): Diffuse Large B-cell Lymphoma with Cyclin D1 Rearrangement vs Mantle Cell Lymphoma?

Hematol Oncol 2020 Jul 8. Epub 2020 Jul 8.

Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, US.

Mantle cell lymphomas (MCLs) are the prototypic B-cell non-Hodgkin lymphomas defined by CCND1 (or other cyclin D family gene) rearrangements. However, extremely rare cases of diffuse large B-cell lymphomas (DLBCLs) harboring CCND1 rearrangements, resulting in cyclin D1 protein expression, have also been reported. In this report, we describe an unusual primary large B-cell lymphoma of non-germinal center immunophenotype of the central nervous system (CNS) in an elderly male patient, which was negative for CD5 and SOX11, and exhibited cyclin D1 expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2779DOI Listing

Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.

Brain Tumor Pathol 2020 Jul 5. Epub 2020 Jul 5.

Department of Pathology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan.

In recent years, the features of lymphomas associated with chronic inflammation, referred to as diffuse large B-cell lymphoma (DLBCL) associated with chronic inflammation (DLBCL-CI), have been elucidated. DLBCL-CI is an aggressive lymphoma occurring in the context of long-standing chronic inflammation and showing an association with Epstein-Barr virus. Fibrin-associated diffuse large B-cell lymphoma (F-DLBCL) was suggested as a new and unusual form of DLBCL-CI in the most recent version of the World Health Organization classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-020-00373-zDOI Listing

[CNS involvement and the feasibility of intratecal chemotherapy administration in patients with a nodal form of diffuse large B-cell lymphoma not otherwise specified. Data of prospective study].

Ter Arkh 2019 Jul 15;91(7):35-40. Epub 2019 Jul 15.

National Research Center for Hematology, Department of Intensive High-Dose Chemotherapy with Round-the-Clock and Day Hospital (IVHT with CS and DS).

Aim of the issue was to determine indications for intratecal chemotherapy drugs administration to prevent relapse of diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement.

Materials And Methods: Since January 2009 to December 2018 102 patients with primary nodal DLBCL over 18 years old were treated in the National Research Center for Hematology, Moscow, Russian Federation. Diagnosis were established in all cases according to histological and immunohistochemical studies which made it possible to exclude the transformation of mature B-cell lymphoma into DLBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.07.000323DOI Listing

Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report.

Clin Case Rep 2020 Jun 8;8(6):933-937. Epub 2020 Apr 8.

Institute of Hematology "L. e A. Seràgnoli" University of Bologna Bologna Italy.

In primary mediastinal large B-cell lymphoma, central nervous system (CNS) relapse is an uncommon event with a dismal prognosis. We report about the successful management of CNS relapse with chemoimmunotherapy according to MATRix (methotrexate, cytarabine, thiotepa, and rituximab) protocol followed by autologous stem cell transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303876PMC

High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma.

Leuk Lymphoma 2020 Jun 23:1-9. Epub 2020 Jun 23.

Division of Hematology Oncology, Center for Oncology Hematology Outcomes Research and Training (COHORT), University of California Davis School of Medicine, Sacramento, CA, USA.

Venous thromboembolism (VTE) and major bleeding in primary central nervous system lymphoma (PCNSL) patients are not well described. We identified 992 PCNSL patients using the California Cancer Registry (2005-2014). The cumulative incidence of VTE and major bleeding was determined using California hospitalization data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1780584DOI Listing

Conventional MR and DW imaging findings of cerebellar primary CNS lymphoma: comparison with high-grade glioma.

Sci Rep 2020 Jun 19;10(1):10007. Epub 2020 Jun 19.

Department of Radiology, Shanxi Provincial People's Hospital, Affiliated People's Hospital of Shanxi Medical University, Taiyuan, 030012, China.

Primary central nervous system lymphomas (PCNSLs) and high-grade gliomas (HGGs) arising in the cerebellum is extremely low, making the differential diagnosis difficult or even impossible. The purpose of this study was to define the MR features of cerebellar PCNSL in immunocompetent patients, and to determine whether a combination of conventional MR and DW imaging can assist in the differentiation of PCNSLs and HGGs. Twelve PCNSLs and 15 HGGs confirmed by pathological analysis were retrospectively identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67080-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305207PMC

Sex-Specific Differences in Primary CNS Lymphoma.

Cancers (Basel) 2020 Jun 16;12(6). Epub 2020 Jun 16.

Division of Neuropathology & Neurochemistry, Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria.

Sex-specific differences have been increasingly recognized in many human diseases including brain cancer, namely glioblastoma. Primary CNS lymphoma (PCNSL) is an exceedingly rare type of brain cancer that tends to have a higher incidence and worse outcomes in male patients. Yet, relatively little is known about the reasons that contribute to these observed sex-specific differences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061593DOI Listing

Primary Sinonasal Lymphoma: A Rare Cause of Cranial Neuropathies.

Cureus 2020 May 15;12(5):e8135. Epub 2020 May 15.

Medicine/Hematology, State University of New York (SUNY) Upstate Medical University, Syracuse, USA.

Primary sinonasal lymphomas are a rare type of non-Hodgkin lymphoma (NHL) with an overall incidence of about 1% of all head and neck cancers. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL and it most commonly occurs in elderly men. The diagnosis of such a lymphoma is difficult because of its varied presentation, which usually occurs late after a significant mass effect has taken place. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294899PMC

Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome.

Eur J Haematol 2020 Jun 16. Epub 2020 Jun 16.

Hematology Unit, Department of Medicine, University of Verona, Verona, Italy.

Primary pancreatic lymphoma (PPL) is a rare disease representing 0.1% of malignant lymphomas, which lacks well-defined diagnostic and therapeutic protocols.

Objectives: To describe PPL clinical, diagnostic and histological characteristics, together with therapy and outcome, in a relatively large series of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13468DOI Listing

High-dose methotrexate in ICU patients: a retrospective study.

Ann Intensive Care 2020 Jun 13;10(1):81. Epub 2020 Jun 13.

Medical ICU, APHP, Saint-Louis Hospital, Paris, France.

Background: High-dose methotrexate (HD-MTX) is commonly used in the treatment of solid tumors and hematological malignancies. Severe toxicities are frequent, leading to organ dysfunction and death. Risk-benefit ratio of using HD-MTX in critically ill patients is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13613-020-00693-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293713PMC

The Role of BAFF-R Signaling in the Growth of Primary Central Nervous System Lymphoma.

Front Oncol 2020 27;10:682. Epub 2020 May 27.

Department of Neurology, Ludwig Maximilians University, Munich, Germany.

Primary CNS lymphoma (PCNSL) is an aggressive brain tumor. Despite improvements in therapeutic algorithms, long-term survival remains rare, illustrating an urgent need for novel therapeutic targets. BAFF-R is a pro-survival receptor expressed on most malignant B cells, including PCNSL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00682DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266954PMC

Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.

Oncologist 2020 Jun 10. Epub 2020 Jun 10.

Massachusetts General Hospital, Boston, Massachusetts, USA.

Lessons Learned: The findings from this study using monotherapy with pemetrexed in a pretreated patient population are, overall, encouraging. Unlike high-dose methotrexate, which requires several days of inpatient hospitalization, pemetrexed is relatively easy to administer in the outpatient setting and remains a viable treatment option in this patient population. The maximum tolerated dose of pemetrexed administered (900 mg/m every 2 weeks) was generally well tolerated and showed activity in patients with relapsed or refractory CNSL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2020-0489DOI Listing
June 2020
4.865 Impact Factor

On point in primary CNS lymphoma.

Hematol Oncol 2020 Jun 8. Epub 2020 Jun 8.

Division of Hematology/Oncology, University of California, San Francisco, California, USA.

Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologies, current options among consolidation strategies, and biological agents. We anticipate that further development of molecular diagnostics and molecular imaging approaches that elucidate minimal residual disease in brain parenchyma, leptomeninges, intraocular compartments and even bone marrow will greatly impact the delivery and timing of cytotoxic and biological therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2761DOI Listing
June 2020
3.084 Impact Factor

[Primary central nervous system lymphoma: advances in treatment strategies].

Authors:
Eisei Kondo

Rinsho Ketsueki 2020 ;61(5):510-519

Department of Hematology, Kawasaki Medical School.

Primary central nervous system (CNS) lymphoma (PCNSL) is a rare subtype of aggressive non-Hodgkin lymphoma originating within the CNS. Whole brain irradiation (WBRT) has been utilized in combination with high-dose methotrexate (HD-MTX), unfortunately with a high rate of late neurocognitive decline, particularly in the elderly. HD-MTX-based combination chemotherapy regimens have been developed as induction therapy for PCNSL and shown to improve response rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.61.510DOI Listing
January 2020

Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.

Hematol Oncol 2020 Jun 7. Epub 2020 Jun 7.

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

High dose methotrexate (HDMTX)-induced acute kidney injury (AKI) is a well-known adverse event in hemato-oncology patients. Our purpose was to define factors and setup cut-offs that may help better identify patients at-risk for developing AKI following HDMTX. All consecutive patients who received MTX dose ≥1 g were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2759DOI Listing

Maculopathy Associated With Osmotic Blood- Brain Barrier Disruption and Chemotherapy in Patients With Primary CNS Lymphoma.

Ophthalmic Surg Lasers Imaging Retina 2020 05;51(5):S5-S12

Background And Objective: To describe the incidence, characteristics, and risk factors of a pigmentary maculopathy in patients with primary central nervous system (CNS) lymphoma treated with blood-brain barrier disruption (BBBD) therapy.

Patients And Methods: This retrospective chart review included patients with biopsy-proven primary CNS lymphoma treated with or without BBBD therapy who underwent an ophthalmic examination after starting systemic treatment. Clinical data and all available retinal imaging were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3928/23258160-20200108-01DOI Listing

A multicentre retrospective study of primary breast diffuse large B-cell and high-grade B-cell lymphoma treatment strategies and survival.

Hematology 2020 Dec;25(1):203-210

Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.

Primary breast diffuse large B-cell lymphoma (PB-DLBCL) and primary breast high-grade B-cell lymphoma (PB-HGBCL) are rare extranodal aggressive B-cell lymphomas with distinct characteristics. Reliable data regarding appropriate treatment of these specific entities are lacking due to their rarity. We reviewed 36 patients diagnosed at four Chinese medical centres between January 2008 and December 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2020.1769419DOI Listing
December 2020

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

J Clin Oncol 2020 May 26:JCO2000303. Epub 2020 May 26.

Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD.

Purpose: Burkitt lymphoma is an aggressive B-cell lymphoma curable with dose-intensive chemotherapy derived from pediatric leukemia regimens. Treatment is acutely toxic with late sequelae. We hypothesized that dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) may obviate the need for highly dose-intensive chemotherapy in adults with Burkitt lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00303DOI Listing
May 2020
18.428 Impact Factor

Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis.

Cancers (Basel) 2020 05 20;12(5). Epub 2020 May 20.

Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.

Lymphoma is listed among the neoplasias with a high risk of venous thromboembolism (VTE). Risk factors for VTE appear to differ from risk factors in solid tumors. We review the literature of the last 20 years for reports identifying these risk factors in cohorts consisting exclusively of lymphoma patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281118PMC

Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects.

CNS Neurol Disord Drug Targets 2020 05 17. Epub 2020 May 17.

Department of Hematology, Beijing Tiantan Hosptal, Capital Medical University, Beijing. China.

Primary central nervous system lymphoma (PCNSL) is a rare invasive extranodal non-Hodgkin lymphoma, the vast majority of which is diffuse large B-cell lymphoma (DLBCL). Although high-dose methotrexate-based immunochemotherapy achieves a high remission rate, the risk of relapse and related death remains a crucial obstruction to long-term survival. Novel agents for the treatment of lymphatic malignancies have greatly broadened the horizons of therapeutic options for PCNSL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871527319666200517112252DOI Listing

Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma.

Blood Res 2020 Jun;55(2):99-106

Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.

Background: This study attempted to identify novel prognostic factors in patients with newly diagnosed primary central nervous system lymphoma (PCNSL) using magnetic resonance imaging (MRI).

Methods: We retrospectively evaluated 67 patients diagnosed with central nervous system (CNS) tumors. The enrollment criteria were as follows: i) pathologic diagnosis of CNS lymphoma, ii) no evidence of systemic involvement, iii) no evidence of human immunodeficiency virus-1 infection or other immunodeficiencies, and iv) MRI scans available at diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5045/br.2020.2020032DOI Listing

Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.

J Neurooncol 2020 Jun 13;148(2):343-352. Epub 2020 May 13.

Médecine Nucléaire, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013, Paris, France.

Introduction: Primary Central Nervous System Lymphoma (PCNSL) is a rare disease with different therapeutic implications than systemic lymphoma. In this study, we evaluated whole-body FDG-PET/CT for pre-chemotherapy imaging of suspected PCNSL.

Methods: One hundred and thirty consecutive immunocompetent patients were retrospectively included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-020-03525-5DOI Listing

Low ADC in CNS Lymphoma.

Clin Nucl Med 2020 Jul;45(7):545-546

Assistance Publique Hôpitaux de Paris, Nuclear Medicine Department, Pitié Salpêtrière-Charles Foix Hospital, AP-HP.

Patients with primary central nervous system lymphomas (PCNSLs) present with nonspecific clinical symptoms, which makes correct imaging evaluation essential for diagnostic and therapeutic management. In this work, we examined an 81-year-old man with recently discovered PCNSL using F-FDG PET/MRI, and we were able to differentiate between 2 lesions-PCNSL lymphoma extension and a recent ischemia. Our work shows that ischemia should be considered as a differential diagnosis for lymphoma progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003067DOI Listing

Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents.

Leukemia 2020 May 11. Epub 2020 May 11.

Department of Pediatric Hematology and Oncology, University of Padova, Padova, Italy.

Data on the spectrum of second malignant neoplasms (SMNs) after primary childhood non-Hodgkin's lymphoma (NHL) are scarce. One-hundred-and-eighty-nine NHL patients diagnosed in a 30 years period of 1980-2010 developing an SMN were retrieved from 19 members of the European Intergroup for Childhood NHL and/or the international Berlin-Frankfurt-Münster Study Group. Five subgroups of SMNs were identified: (1) myeloid neoplasms (n = 43; 23%), (2) lymphoid neoplasms (n = 51; 27%), (3) carcinomas (n = 48; 25%), (4) central nervous system (CNS) tumors (n = 19; 10%), and (5) "other" SMNs (n = 28; 15%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0841-xDOI Listing
May 2020
10.431 Impact Factor

Molecular Diagnostics in Lymphoid Neoplasms of the Central Nervous System.

Authors:
David M Meredith

Surg Pathol Clin 2020 Jun 7;13(2):267-276. Epub 2020 Apr 7.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address:

Primary lymphoid neoplasms of the central nervous system are rare tumors that span a wide range of histopathologic appearances and can overlap occasionally with non-neoplastic processes. Application of modern molecular techniques has not only begun to unravel their unique underlying biology but has also started to lay a valuable diagnostic and therapeutic framework for these frequently aggressive malignancies. This review summarizes the existing landscape of clinicopathologic and genomic features of lymphoid neoplasms that may arise primarily within the central nervous system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.path.2020.02.001DOI Listing

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis.

Blood Adv 2020 May;4(9):1906-1915

Department of Oncology, Oslo University Hospital and KG Jebsen Centre for B Cell Malignancies, Oslo, Norway.

Survival of patients with high-risk diffuse large B-cell lymphoma (DLBCL) is suboptimal, and the risk of central nervous system (CNS) progression is relatively high. We conducted a phase 2 trial in 139 patients aged 18 to 64 years who had primary DLBCL with an age-adjusted International Prognostic Index (aaIPI) score of 2 to 3 or site-specific risk factors for CNS recurrence. The goal was to assess whether a dose-dense immunochemotherapy with early systemic CNS prophylaxis improves the outcome and reduces the incidence of CNS events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001518DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218416PMC

Redox reaction and clinical outcome of primary diffuse large B-cell lymphoma of the central nervous system: Prognostic role of metabolic and textural parameters of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/computed tomography in a small patient cohort.

Nucl Med Commun 2020 Jun;41(6):567-574

Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University.

Objective: This study aimed to clarify the relationship between tumor redox reaction evaluated by Cu-diacetyl-bis (N4-methylthiosemicarbazone) (Cu-ATSM) PET/computed tomography (CT) and disease-free survival (DFS) in patients with primary diffuse large B-cell lymphoma of the central nervous system (DLBCL-CNS).

Methods: Fifteen consecutive patients with histologically confirmed DLBCL-CNS underwent preoperative Cu-ATSM PET/CT and F-fluorodeoxyglucose (FDG) PET/CT. Statistical features of seven first-order parameters, including the standardized uptake value (SUV); 12 second-order parameters, including gray-level co-occurrence matrices and gray-level zone size matrices; and 5 high-order parameters, including neighborhood gray-tone difference matrices, were calculated from the volume of interest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000001197DOI Listing
June 2020
1.371 Impact Factor

In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.

Cancer Immunol Immunother 2020 Apr 25. Epub 2020 Apr 25.

Translational Cell and Tissue Research Lab, Department of Imaging and Pathology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.

Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma with an aggressive clinical course. To investigate the potential of immune-checkpoint therapy, we retrospectively studied the tumor microenvironment (TME) using high-plex immunohistochemistry in 22 PCNSL and compared to 7 secondary CNS lymphomas (SCNSL) and 7 "other" CNSL lymphomas with the presence of the Epstein-Barr virus and/or compromised immunity. The TME in PCNSL was predominantly composed of CD8+ cytotoxic T cells and CD163+ phagocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-020-02575-yDOI Listing

CXCR4-targeted positron emission tomography imaging of central nervous system B-cell lymphoma.

J Nucl Med 2020 Apr 24. Epub 2020 Apr 24.

Hematology, Oncology, and Tumor Immunology (Campus Benjamin Franklin), Charite - Universitaetsmedizin Berlin, Berlin, Germany.

C-X-C chemokine receptor 4 is a transmembrane chemokine receptor involved in growth, survival, and dissemination of cancer, including aggressive B-cell lymphoma. Magnetic resonance imaging (MRI) is the standard imaging technology for central nervous system involvement of B-cell lymphoma and provides high sensitivity but moderate specificity. Therefore, novel molecular and functional imaging strategies are urgently required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.120.241703DOI Listing

CNS lymphoma, the Irish experience: A retrospective review of neuropathologically confirmed cases over 10 years.

Clin Neuropathol 2020 Apr 17. Epub 2020 Apr 17.

Background: Central nervous system (CNS) lymphoma is rare, representing 2% of all brain tumors. The commonest subtype is diffuse large B-cell lymphoma (DLBCL), with primary T-cell lymphomas (PCNSTL) accounting for ~ 2%.

Objective: To determine the frequency and describe the key features of CNS lymphoma over a 10-year period in an Irish population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5414/NP301252DOI Listing

Maintenance of multi-domain neurocognitive functions in patients with newly-diagnosed primary CNS lymphoma after primary cranial radiotherapy combined with methotrexate-based chemotherapy: A preliminary case-series study.

Appl Neuropsychol Adult 2020 Apr 17:1-10. Epub 2020 Apr 17.

Department of Psychology, National Chengchi University, Taipei, Taiwan.

Conventional treatment for treating primary central nervous system lymphoma (PCNSL) has consisted of either whole-brain radiotherapy (WBRT) or methotrexate (MTX)-based combined modality therapy. However, delayed cognitive sequelae have emerged as a significant debilitating complication in PCNSL patients. A prospective observational case-series study with prospective assessments of neurocognitive functions (NCFs), neuroimaging, and activities of daily living in newly-diagnosed PCNSL patients was undertaken. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23279095.2020.1749630DOI Listing

Parkinsonism as a late presentation of lymphomatosis cerebri following high-dose chemotherapy with autologous stem cell transplantation for primary central nervous system lymphoma.

J Neurol 2020 Apr 15. Epub 2020 Apr 15.

Department of Medicine, Division of Hematology and Oncology, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA.

Primary central nervous system lymphoma is an aggressive form of non-Hodgkin lymphoma arising in the eyes, meninges, spinal cord, or brain. Treatment of primary CNS lymphoma with a combination of high-dose chemotherapy and autologous stem cell transplantation has been shown to have high rates of remission which is frequently sustained for multiple years. Recurrence of primary CNS lymphoma generally presents with one or multiple contrast enhancing lesions on MRI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-020-09819-yDOI Listing

Cranial vault lymphoma- An unusual presentation of primary disease.

J Pak Med Assoc 2020 Apr;70(4):767-768

Department of Radiology, ShaukatKhanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.

Diffuse cranial vault and concurrent dural based disease involvement by primary CNS lymphoma is extremely rare. Often such presentations are overlooked initially as benign lesions and biopsy of lymph nodes elsewhere remains source of diagnosis in majority of patients. Diffuse large B-cell lymphoma is a subtype of primary CNS lymphoma with subdural involvement that is diagnosed based on imaging. Read More

View Article

Download full-text PDF

Source

Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis.

Cancers (Basel) 2020 Apr 10;12(4). Epub 2020 Apr 10.

Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.

To date, no head-to-head trials have compared the efficacy of brigatinib and alectinib against anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p), ALK-inhibitor-naïve, advanced non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. We conducted an indirect treatment comparison (ITC) between brigatinib and alectinib, with crizotinib as a common comparator, using a Bayesian model with non-informative prior distribution and assessed the between-study heterogeneity of the studies. The primary efficacy endpoint was progression-free survival (PFS), and efficacy was ranked using the surface under the cumulative ranking (SUCRA) curve values. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12040942DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226463PMC

Expression and Function of Toll-Like Receptor 10 (TLR10) in Diffuse Large B Cell Lymphoma, Acute Myeloid Leukemia, and Glioma.

Med Sci Monit 2020 Apr 14;26:e921500. Epub 2020 Apr 14.

Tianjin Neurosurgical Institute, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin Huanhu Hospital, Tianjin, China (mainland).

BACKGROUND Toll-like receptor (TLR) family members are part of the major pathogen-recognition system for innate immunity. TLR10, the only remaining orphan receptor with an unknown ligand, has been poorly studied in tumors, and its functional and clinical relevance are unclear. MATERIAL AND METHODS We analyzed TLR10 expression data in The Cancer Genome Atlas (TCGA) by established computational approaches (UALCAN, GEPIA, CGGA, and TIMER) and confirmed them by immunohistochemistry analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.921500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174897PMC

Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review.

Rheumatol Int 2020 Apr 6. Epub 2020 Apr 6.

Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.

Primary central nervous system lymphoma (PCNSL) sometimes occurs in immune-compromised hosts or patients with autoimmune diseases. Some cohort studies have previously reported an increased risk of non-Hodgkin's lymphoma in systemic lupus erythematosus (SLE), while some cases of PCNSL in patients with SLE were reported. We present the case of PCNSL which developed in a patient with the active phase of neuropsychiatric SLE (NPSLE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-020-04569-6DOI Listing

Facial nerve paralysis in 64 equids: Clinical variables, diagnosis, and outcome.

J Vet Intern Med 2020 May 6;34(3):1308-1320. Epub 2020 Apr 6.

Department of Clinical Studies, New Bolton Center, University of Pennsylvania, Kennett Square, Pennsylvania, USA.

Background: Facial nerve paralysis (FNP) in equids is not well described in the veterinary literature.

Objective: To investigate the causes of FNP and associations among clinical variables, diagnosis, and outcome.

Animals: Sixty-four equids presenting with FNP between July 2000 and April 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvim.15767DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255662PMC

Primary Central Nervous System Lymphoma in a Patient on Adalimumab Therapy for Chronic Plaque Psoriasis.

World Neurosurg 2020 Apr 2;139:260-263. Epub 2020 Apr 2.

Neurosurgery Department, American Hospital, Dubai, United Arab Emirates. Electronic address:

Background: Adalimumab (Humira) is a recombinant human monoclonal antibody against tumor necrosis factor alpha, which works by blocking the interaction of tumor necrosis factor alpha with its cell-surface receptors, thereby limiting the progression of inflammatory pathways. Its use is approved for several autoimmune conditions, including chronic plaque psoriasis, for which it has been prescribed as a first-line biologic treatment. Increased risks of malignancy, particularly nonmelanoma skin cancer and non-central nervous system lymphomas, have been reported with use of this drug; however, there have been no reports of central nervous system lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2020.03.155DOI Listing

Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.

Clin Lymphoma Myeloma Leuk 2020 Jul 20;20(7):468-479. Epub 2020 Feb 20.

Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

Background: High-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) has been investigated in patients with primary central nervous system lymphoma (PCNSL) and non-Hodgkin lymphoma (NHL) with CNS involvement and has shown promising results.

Patients And Methods: A retrospective analysis was performed of 48 consecutive patients who had undergone HDC/ASCT with TBC (thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS lymphoma (SCNSL) (8 patients), or relapsed disease with CNS involvement (13 patients) from July 2006 to December 2017. Of the 27 patients with PCNSL, 21 had undergone ASCT at first complete remission (CR1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.02.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138188PMC

Cerebrospinal Fluid Flow Cytometry: Utility in Central Nervous System Lymphoma Diagnosis.

Can J Neurol Sci 2020 05;47(3):382-388

Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.

Background: Flow cytometry of the cerebrospinal fluid (CSF) is used in isolation or as an adjunct to cytology to increase the sensitivity of detecting central nervous system (CNS) lymphoma. We aimed to evaluate the sensitivity of CSF flow cytometry as a diagnostic screening tool for primary CNS lymphoma in patients presenting with undifferentiated neurologic symptoms.

Methods: We retrospectively reviewed all CSF samples received by the Calgary Laboratory Services Flow Cytometry Laboratory from 2012 to 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/cjn.2020.22DOI Listing

Primary CNS lymphoma commonly expresses immune response biomarkers.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa018. Epub 2020 Feb 19.

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Background: Primary central nervous system lymphoma (PCNSL) is rare and there is limited genomic and immunological information available. Incidental clinical and radiographic responses have been reported in PCNSL patients treated with immune checkpoint inhibitors.

Materials And Methods: To genetically characterize and ascertain if the majority of PCNSL patients may potentially benefit from immune checkpoint inhibitors, we profiled 48 subjects with PCNSL from 2013 to 2018 with (1) next-generation sequencing to detect mutations, gene amplifications, and microsatellite instability (MSI); (2) RNA sequencing to detect gene fusions; and (3) immunohistochemistry to ascertain PD-1 and PD-L1 expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067145PMC
February 2020

The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma.

Haematologica 2020 Mar 19. Epub 2020 Mar 19.

Institute of Neuropathology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany;

The immunoglobulin (Ig) heavy and light chain variable gene mutational pattern of the B cell receptor (BCR) in primary central nervous system (CNS) lymphoma (PCNSL) cells suggests antigenic selection to drive pathogenesis and confinement to the CNS. This hypothesis is supported by the observation that the tumor B cell receptor (tBCR) of PCNSL is polyreactive and may be stimulated by CNS proteins. To obtain further insight into the role of the germinal center (GC) reaction on BCR reactivity, we constructed recombinant antibodies (recAb) with Ig heavy and light chain sequences of the corresponding naive BCR (nBCR) by reverting tBCR somatic mutations in 10 PCNSL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.242701DOI Listing

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.

Lancet Oncol 2020 04 17;21(4):541-550. Epub 2020 Mar 17.

Department of Pediatrics, Division of Hematology and Oncology, Stanford University, Stanford, CA, USA. Electronic address:

Background: Immune checkpoint inhibitors targeting PD-1 have shown clinical benefit in adults with cancer, but data on these drugs in children are scarce. We did a phase 1-2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determine its safety, pharmacokinetics, and antitumour activity in children and young adults with recurrent or refractory non-CNS solid tumours or lymphoma.

Methods: We did a multicentre, open-label, single-arm, dose-confirmation and dose-expansion, phase 1-2 trial in 23 hospitals in the USA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30023-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255545PMC

Primary CNS lymphoma initially diagnosed as vasculitis.

Neurol Clin Pract 2020 Feb;10(1):84-88

Neurological Institute, Cleveland Clinic, OH.

Purpose Of Review: A vasculitic pattern of injury seen on brain biopsy can be attributed to a multitude of primary or secondary disorders, leading to diagnostic challenges for clinicians.

Recent Findings: This report describes the clinical presentation and histopathologic findings in 2 patients who initially received a diagnosis of primary CNS vasculitis, but did not show long-term response to treatment. In both cases, a second biopsy was performed, and the final diagnosis was primary CNS lymphoma (PCNSL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CPJ.0000000000000693DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057073PMC
February 2020